Efficacy and Safety of the Vasopressin V1A/V2-Receptor Antagonist Conivaptan in Acute Decompensated Heart Failure: A Dose-Ranging Pilot Study

Journal of Cardiac Failure

Volumn 14, Issue 8, 2008, Pages 641-647

  Goldsmith, Steven R ^a   Elkayam, Uri ^b   Haught, W Herbert ^c   Barve, Abhijit ^d   He, Weizhong ^d  

^a UNIVERSITY OF MINNESOTA   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c HUNTSVILLE HOSPITAL   (United States)

^d ASTELLAS PHARMA GLOBAL DEVELOPMENT   (United States)

Author keywords

Acute heart failure; aquaresis; diuresis

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CONIVAPTAN; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FUROSEMIDE; HYDRALAZINE; METOLAZONE; NESIRITIDE; PLACEBO; SPIRONOLACTONE; TORASEMIDE; VASODILATOR AGENT;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISSEMINATED INTRAVASCULAR CLOTTING; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG TOLERABILITY; ELECTROLYTE DISTURBANCE; FEMALE; HEART FAILURE; HEART RHYTHM; HEART VENTRICLE FIBRILLATION; HEART VENTRICLE TACHYCARDIA; HUMAN; KIDNEY FAILURE; LUNG COMPLICATION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE ORGAN FAILURE; PATIENT ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEPSIS; URINE VOLUME;

ACUTE DISEASE; AGED; AREA UNDER CURVE; BENZAZEPINES; DISEASE PROGRESSION; DIURESIS; DOUBLE-BLIND METHOD; FEMALE; HEART FAILURE; HUMANS; MALE; MIDDLE AGED; PAIN MEASUREMENT; PILOT PROJECTS; RECEPTORS, VASOPRESSIN; VASOPRESSINS;

EID: 52949114492     PISSN: 10719164     EISSN: 15328414     Source Type: Journal    
DOI: 10.1016/j.cardfail.2008.06.003     Document Type: Article

References (27)

1. Congestive heart failure in the United States: a new epidemic. Data Fact Sheet. http://library.thinkquest.org/27533/ Available at: facts.html Accessed August 2, 2007
2. Felker G.M., Adams Jr. K.F., Konstam M.A., O'Connor C.M., and Gheorghiade M. The problem of decompensated heart failure: nomenclature, classification, and risk stratification. Am Heart J 145 Suppl 2 (2003) S18-S25
3. Fonarow G.C. ADHERE Scientific Advisory Committee. The Acute Decompensated Heart Failure National Registry (ADHERE): opportunities to improve care of patients hospitalized with acute decompensated heart failure. Rev Cardiovasc Med 4 suppl 7 (2003) S21-S30
4. Cuffe M.S., Califf R.M., Adams Jr. K.F., Benza R., Bourge R., Colucci W.S., et al. Short-term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial. JAMA 287 (2002) 1541-1547
5. Gheorghiade M., Zannad F., Sopko G., Klein L., Piña I.L., Konstam M.A., et al. International Working Group on Acute Heart Failure Syndromes. Acute heart failure syndromes: current state and framework for future research. Circulation 112 (2005) 3958-3968
6. Vinson J.M., Rich M.W., Sperry J.C., Shah A.S., and McNamara T. Early readmission of elderly patients with congestive heart failure. J Am Geriatr Soc 38 (1990) 1290-1295
7. Krumholz H.M., Parent E.M., Tu N., Vaccarino V., Wang Y., Radford M.J., et al. Readmission after hospitalization for congestive heart failure among Medicare beneficiaries. Arch Intern Med 157 (1997) 99-104
8. Heart Failure Society of America. Executive summary: HFSA 2006 Comprehensive Heart Failure Practice Guideline. J Card Fail 12 (2006) 10-38
9. Gheorghiade M. The clinical effects of vasopressin receptor antagonists in heart failure. Cleve Clin J Med 73 Suppl 2 (2006) S24-S29
10. Gheorghiade M., Konstam M.A., Burnett Jr. J.C., Grinfeld L., Maggioni A.P., Swedberg K., et al. Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study With Tolvaptan (EVEREST) Investigators. Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status Trials. JAMA 297 (2007) 1332-1343
11. Konstam M.A., Gheorghiade M., Burnett Jr. J.C., Grinfeld L., Maggioni A.P., Swedberg K., et al. Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study With Tolvaptan (EVEREST) Investigators. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial. JAMA 297 (2007) 1319-1331
12. Sharma M., and Teerlink J.R. A rational approach for the treatment of acute heart failure: current strategies and future options. Curr Opin Cardiol 19 (2004) 254-263
13. Cheng J.W. Tezosentan in the management of decompensated heart failure. Cardiol Rev 13 (2005) 28-34
14. Costanzo M.R., Guglin M.E., Saltzberg M.T., Jessup M.L., Bart B.A., and Teerlink J.R. et al, for the UNLOAD Trial Investigators. Ultrafiltration versus intravenous diuretics for patients hospitalized for acute decompensated heart failure. J Am Coll Cardiol 49 (2007) 675-683
15. Szatalowicz V.L., Arnold P.E., Chaimovitz C., Bichet D., Berl T., and Schrier R.W. Radioimmunoassay of plasma arginine vasopressin in hyponatremic patients with congestive heart failure. N Engl J Med 305 (1981) 263-266
16. Riegger G.A., Liebau G., and Kochsiek K. Antidiuretic hormone in congestive heart failure. Am J Med 72 (1982) 49-52
17. Goldsmith S.R., Francis G.S., Cowley Jr. A.W., Levine T.B., and Cohn J.N. Increased plasma arginine vasopressin levels in patients with congestive heart failure. J Am Coll Cardiol 1 (1983) 1385-1390
18. Wong L.L., and Verbalis J.G. Systemic diseases associated with disorders of water homeostasis. Endocrinol Metab Clin North Am 31 (2002) 121-140
19. Goldsmith S.R. Vasopressin antagonists in CHF: ready for clinical trials?. Cardiovasc Res 54 (2002) 13-15
20. Goldsmith S.R., and Gheorghiade M. Vasopressin antagonism in heart failure. J Am Coll Cardiol 46 (2005) 1785-1791
21. 2 receptor antagonist, in vitro and in vivo. J Pharmacol Exp Ther 282 (1997) 301-308
22. 2 receptor antagonist, in dogs with pacing-induced congestive heart failure. Eur J Pharmacol 376 (1999) 239-246
23. 2 vasopressin receptor antagonist, in patients with advanced heart failure. Circulation 104 (2001) 2417-2423
24. 2 vasopressin receptor antagonist in normal subjects. Eur J Clin Pharmacol 55 (1999) 633-637
25. Zeltser D., Rosansky S., van Rensburg H., Verbalis J.G., and Smith N. Assessment of the efficacy and safety of intravenous conivaptan in euvolemic and hypervolemic hyponatremia. Am J Nephrol 27 (2007) 447-457
26. Mebazaa A., Nieminen M.S., Packer M., Cohen-Solal A., Kleber F.X., Pocock S.J., et al. SURVIVE Investigators. Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE Randomized Trial. JAMA 297 (2007) 1883-1891
27. Chatterjee K. Neurohormonal activation in congestive heart failure and the role of vasopressin. Am J Cardiol 95 Suppl (2005) 8B-13B